<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33508894</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Interfering with lysophosphatidic acid receptor edg2/lpa<sub>1</sub> signalling slows down disease progression in SOD1-G93A transgenic mice.</ArticleTitle><Pagination><StartPage>1004</StartPage><EndPage>1018</EndPage><MedlinePgn>1004-1018</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12699</ELocationID><Abstract><AbstractText Label="AIMS">Alterations in excitability represent an early hallmark in Amyotrophic Lateral Sclerosis (ALS). Therefore, deciphering the factors that impact motor neuron (MN) excitability offers an opportunity to uncover further aetiopathogenic mechanisms, neuroprotective agents, therapeutic targets, and/or biomarkers in ALS. Here, we hypothesised that the lipokine lysophosphatidic acid (lpa) regulates MN excitability via the G-protein-coupled receptor lpa<sub>1</sub> . Then, modulating lpa<sub>1</sub> -mediated signalling might affect disease progression in the ALS SOD1-G93A mouse model.</AbstractText><AbstractText Label="METHODS">The influence of lpa-lpa<sub>1</sub> signalling on the electrical properties, Ca<sup>2+</sup> dynamic and survival of MNs was tested in vitro. Expression of lpa<sub>1</sub> in cultured MNs and in the spinal cord of SOD1-G93A mice was analysed. ALS mice were chronically treated with a small-interfering RNA against lpa<sub>1</sub> (siRNA<sub>lpa1</sub> ) or with the lpa<sub>1</sub> inhibitor AM095. Motor skills, MN loss, and lifespan were evaluated.</AbstractText><AbstractText Label="RESULTS">AM095 reduced MN excitability. Conversely, exogenous lpa increased MN excitability by modulating task1 'leak' potassium channels downstream of lpa<sub>1</sub> . Lpa-lpa<sub>1</sub> signalling evoked an excitotoxic response in MNs via voltage-sensitive calcium channels. Cultured SOD1-G93A MNs displayed lpa<sub>1</sub> upregulation and heightened vulnerability to lpa. In transgenic mice, lpa<sub>1</sub> was upregulated mostly in spinal cord MNs before cell loss. Chronic administration of either siRNA<sub>lpa1</sub> or AM095 reduced lpa<sub>1</sub> expression at least in MNs, delayed MN death, improved motor skills, and prolonged life expectancy of ALS mice.</AbstractText><AbstractText Label="CONCLUSIONS">These results suggest that stressed lpa-lpa<sub>1</sub> signalling contributes to MN degeneration in SOD1-G93A mice. Consequently, disrupting lpa<sub>1</sub> slows down disease progression. This highlights LPA<sub>1</sub> signalling as a potential target and/or biomarker in ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 British Neuropathological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gento-Caro</LastName><ForeName>&#xc1;ngela</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Grupo de Neurodegeneraci&#xf3;n y Neurorreparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz, C&#xe1;diz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilches-Herrando</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Grupo de Neurodegeneraci&#xf3;n y Neurorreparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz, C&#xe1;diz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Morales</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-8964-9935</Identifier><AffiliationInfo><Affiliation>Grupo de Neurodegeneraci&#xf3;n y Neurorreparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz, C&#xe1;diz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portillo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurodegeneraci&#xf3;n y Neurorreparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz, C&#xe1;diz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Bey</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Grupo de Neurodegeneraci&#xf3;n y Neurorreparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz, C&#xe1;diz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Forero</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Grupo de Neurodegeneraci&#xf3;n y Neurorreparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz, C&#xe1;diz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-L&#xf3;pez</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2897-6227</Identifier><AffiliationInfo><Affiliation>Grupo de Neurodegeneraci&#xf3;n y Neurorreparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz, C&#xe1;diz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D049368">Receptors, Lysophosphatidic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049368" MajorTopicYN="N">Receptors, Lysophosphatidic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1-G93A model</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">background potassium channels</Keyword><Keyword MajorTopicYN="N">excitotoxicity</Keyword><Keyword MajorTopicYN="N">intrinsic membrane excitability</Keyword><Keyword MajorTopicYN="N">lpa1/edg2/vzg1</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>28</Day><Hour>20</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33508894</ArticleId><ArticleId IdType="doi">10.1111/nan.12699</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Fogarty MJ. Driven to decay: excitability and synaptic abnormalities in amyotrophic lateral sclerosis. Brain Res Bull. 2018;140:318-333. https://doi.org/10.1016/j.brainresbull.2018.05.023</Citation></Reference><Reference><Citation>Fratta P, Isaacs AM. The snowball effect of RNA binding protein dysfunction in amyotrophic lateral sclerosis. Brain. 2018;141(5):1236-1238. https://doi.org/10.1093/brain/awy091</Citation></Reference><Reference><Citation>Konopka A, Atkin JD. The emerging role of DNA damage in the pathogenesis of the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Int J Mol Sci. 2018;19(10):3137. https://doi.org/10.3390/ijms19103137</Citation></Reference><Reference><Citation>Ruegsegger C, Saxena S. Proteostasis impairment in ALS. Brain Res. 2016;1648:571-579. https://doi.org/10.1016/j.brainres.2016.03.032</Citation></Reference><Reference><Citation>Kim HJ, Taylor JP. Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron. 2017;96(2):285-297. https://doi.org/10.1016/j.neuron.2017.07.029</Citation></Reference><Reference><Citation>Do-Ha D, Buskila Y, Ooi L. Impairments in motor neurons, interneurons and astrocytes contribute to hyperexcitability in ALS: underlying mechanisms and paths to therapy. Mol Neurobiol. 2018;55(2):1410-1418. https://doi.org/10.1007/s12035-017-0392-y</Citation></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2016;1:162-171. https://doi.org/10.1016/j.expneurol.2015.09.019</Citation></Reference><Reference><Citation>Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12(3):310-322.</Citation></Reference><Reference><Citation>Bae JS, Simon NG, Menon P, Vucic S, Kiernan MC. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol. 2013;9(2):65-74. https://doi.org/10.3988/jcn.2013.9.2.65</Citation></Reference><Reference><Citation>Ragagnin AMG, Shadfar S, Vidal M, Jamali MS, Atkin JD. Motor neuron susceptibility in ALS/FTD. Front Neurosci. 2019;13:532. https://doi.org/10.3389/fnins.2019.00532</Citation></Reference><Reference><Citation>Kanai K, Shibuya K, Sato Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734-738. https://doi.org/10.1136/jnnp-2011-301782</Citation></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761-772. https://doi.org/10.1083/jcb.200908164</Citation></Reference><Reference><Citation>Garc&#xed;a-Morales V, Rodr&#xed;guez-Bey G, G&#xf3;mez-P&#xe9;rez L, et al. Sp1-regulated expression of p11 contributes to motor neuron degeneration by membrane insertion of TASK1. Nat Commun. 2019;10:3784.</Citation></Reference><Reference><Citation>Devlin AC, Burr K, Borooah S, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6:5999. https://doi.org/10.1038/ncomms6999</Citation></Reference><Reference><Citation>Kim J, Hughes EG, Shetty AS, et al. Changes in the excitability of neocortical neurons in a mouse model of amyotrophic lateral sclerosis are not specific to corticospinal neurons and are modulated by advancing disease. J Neurosci. 2017;37(37):9037-9053. https://doi.org/10.1523/JNEUROSCI.0811-17.2017</Citation></Reference><Reference><Citation>Leroy F, Lamotte d&#x2019;Incamps B, Imhoff-Manuel RD, Zytnicki D. Early intrinsic hyperexcitability does not contribute to motoneuron degeneration in amyotrophic lateral sclerosis. Elife. 2014;3:e04046. https://doi.org/10.7554/eLife.04046</Citation></Reference><Reference><Citation>Saxena S, Roselli F, Singh K, et al. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron. 2013;80(1):80-96. https://doi.org/10.1016/j.neuron.2013.07.027</Citation></Reference><Reference><Citation>Martinez-Silva ML, Imhoff-Manuel RD, Sharma A, et al. Hypoexcitability precedes denervation in the large fast-contracting motor units in two unrelated mouse models of ALS. Elife. 2018;7:e30955. https://doi.org/10.7554/eLife.30955</Citation></Reference><Reference><Citation>Fuchs B, Schiller J. Lysophospholipids: their generation, physiological role and detection. Are they important disease markers? Mini Rev Med Chem. 2009;9(3):368-378.</Citation></Reference><Reference><Citation>Herr DR, Chew WS, Satish RL, Ong WY. Pleotropic roles of autotaxin in the nervous system present opportunities for the development of novel therapeutics for neurological diseases. Mol Neurobiol. 2020;57:372-392. https://doi.org/10.1007/s12035-019-01719-1</Citation></Reference><Reference><Citation>Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134(6):933-944. https://doi.org/10.1016/j.cell.2008.07.048</Citation></Reference><Reference><Citation>Lee THY, Cheng KKY, Hoo RLC, Siu PMF, Yau SY. The novel perspectives of adipokines on brain health. Int J Mol Sci. 2019;20(22):5638. https://doi.org/10.3390/ijms20225638</Citation></Reference><Reference><Citation>Parimisetty A, Dorsemans A, Awada R, Ravanan P, Diotel N, Lefebvre DC. Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research. J Neuroinflammation. 2016;13(1):67. https://doi.org/10.1186/s12974-016-0530-x</Citation></Reference><Reference><Citation>Choi JW, Chun J. Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta. 2013;1831(1):20-32. https://doi.org/10.1016/j.bbalip.2012.07.015</Citation></Reference><Reference><Citation>Lee HY, Murata J, Clair T, et al. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun. 1996;218(3):714-719. https://doi.org/10.1006/bbrc.1996.0127</Citation></Reference><Reference><Citation>Das AK, Hajra AK. Quantification, characterization and fatty acid composition of lysophosphatidic acid in different rat tissues. Lipids. 1989;24(4):329-333. https://doi.org/10.1007/BF02535172</Citation></Reference><Reference><Citation>Garc&#xed;a-Morales V, Montero F, Gonz&#xe1;lez-Forero D, et al. Membrane-derived phospholipids control synaptic neurotransmission and plasticity. PLoS Biol. 2015;13(5):e1002153. https://doi.org/10.1371/journal.pbio.1002153</Citation></Reference><Reference><Citation>Seyler C, Duthil-Straub E, Zitron E, et al. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation. Br J Pharmacol. 2012;165(5):1467-1475. https://doi.org/10.1111/j.1476-5381.2011.01626.x</Citation></Reference><Reference><Citation>Hanrieder J, Ewing AG. Spatial elucidation of spinal cord lipid- and metabolite- regulations in amyotrophic lateral sclerosis. Sci Rep. 2014;4:5266. https://doi.org/10.1038/srep05266</Citation></Reference><Reference><Citation>Blasco H, Veyrat-Durebex C, Bocca C, et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep. 2017;7:17652. https://doi.org/10.1038/s41598-017-17389-9</Citation></Reference><Reference><Citation>Yung YC, Stoddard NC, Mirendil H, Chun J. Lysophosphatidic acid signaling in the nervous system. Neuron. 2015;85(4):669-682. https://doi.org/10.1016/j.neuron.2015.01.009</Citation></Reference><Reference><Citation>Shibata N, Kakita A, Takahashi H, et al. Increased expression and activation of cytosolic phospholipase A2 in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2010;119(3):345-354. https://doi.org/10.1007/s00401-009-0636-7</Citation></Reference><Reference><Citation>Kiaei M, Kipiani K, Petri S, et al. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005;93(2):403-411. https://doi.org/10.1111/j.1471-4159.2005.03024.x</Citation></Reference><Reference><Citation>Solomonov Y, Hadad N, Levy R. Reduction of cytosolic phospholipase A2alpha upregulation delays the onset of symptoms in SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13(1):134. https://doi.org/10.1186/s12974-016-0602-y</Citation></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, et al. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89(5):718-728. https://doi.org/10.1002/jnr.22594</Citation></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol. 1984;6(1):51-57. https://doi.org/10.1016/0165-5728(84)90042-0</Citation></Reference><Reference><Citation>Lewandowski SA, Fredriksson L, Lawrence DA, Eriksson U. Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders. Pharmacol Ther. 2016;167:108-119. https://doi.org/10.1016/j.pharmthera.2016.07.016</Citation></Reference><Reference><Citation>Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Physiol. 1995;268(5 Pt 2):H2048-H2055. https://doi.org/10.1152/ajpheart.1995.268.5.H2048</Citation></Reference><Reference><Citation>Pan HL, Liu BL, Lin W, Zhang YQ. Modulation of Nav1.8 by lysophosphatidic acid in the induction of bone cancer pain. Neurosci Bull. 2016;32(5):445-454. https://doi.org/10.1007/s12264-016-0060-7</Citation></Reference><Reference><Citation>Lee JC, Park SM, Kim IY, Sung H, Seong JK, Moon MH. High-fat diet-induced lipidome perturbations in the cortex, hippocampus, hypothalamus, and olfactory bulb of mice. Biochim Biophys Acta - Mol Cell Biol Lipids. 2018;1863(9):980-990. https://doi.org/10.1016/j.bbalip.2018.05.007</Citation></Reference><Reference><Citation>Rancoule C, Dusaulcy R, Treguer K, Gres S, Attane C, Saulnier-Blache JS. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie. 2014;96:140-143. https://doi.org/10.1016/j.biochi.2013.04.010</Citation></Reference><Reference><Citation>Ning P, Yang B, Li S, et al. Systematic review of the prognostic role of body mass index in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2019;20(5-6):356-367. https://doi.org/10.1080/21678421.2019.1587631</Citation></Reference><Reference><Citation>Garc&#xed;a-Morales V, Montero F, Moreno-L&#xf3;pez B. Cannabinoid agonists rearrange synaptic vesicles at excitatory synapses and depress motoneuron activity in vivo. Neuropharmacology. 2015;92:69-79.</Citation></Reference><Reference><Citation>Gonz&#xe1;lez-Forero D, Montero F, Garc&#xed;a-Morales V, et al. Endogenous rho-kinase signaling maintains synaptic strength by stabilizing the size of the readily releasable pool of synaptic vesicles. J Neurosci. 2012;32(1):68-84.</Citation></Reference><Reference><Citation>Gonz&#xe1;lez-Forero D, Portillo F, G&#xf3;mez L, Montero F, Kasparov S, Moreno-L&#xf3;pez B. Inhibition of resting potassium conductances by long-term activation of the NO/cGMP/protein kinase G pathway: a new mechanism regulating neuronal excitability. J Neurosci. 2007;27(23):6302-6312.</Citation></Reference><Reference><Citation>Portillo F, Moreno-L&#xf3;pez B. Nitric oxide controls excitatory/inhibitory balance in the hypoglossal nucleus during early postnatal development. Brain Struct Funct. 2020;225(9):2871-2884. https://doi.org/10.1007/s00429-020-02165-9</Citation></Reference><Reference><Citation>Roselli F, Caroni P. From intrinsic firing properties to selective neuronal vulnerability in neurodegenerative diseases. Neuron. 2015;85(5):901-910. https://doi.org/10.1016/j.neuron.2014.12.063</Citation></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011;71(1):35-48. https://doi.org/10.1016/j.neuron.2011.06.031</Citation></Reference><Reference><Citation>Sugiura T, Nakane S, Kishimoto S, et al. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta. 1999;1440(2-3):194-204. https://doi.org/10.1016/S1388-1981(99)00127-4</Citation></Reference><Reference><Citation>Holtsberg FW, Steiner MR, Keller JN, Mark RJ, Mattson MP, Steiner SM. Lysophosphatidic acid induces necrosis and apoptosis in hippocampal neurons. J Neurochem. 1998;70(1):66-76. https://doi.org/10.1046/j.1471-4159.1998.70010066.x</Citation></Reference><Reference><Citation>Zhu L, Zhu J, Guo SW. Homer1/mGluR1-mediated ER stress contributes to lysophosphatidic acid-induced neurotoxicity in cortical neurons. Neurochem Int 2019;129:104515. https://doi.org/10.1016/j.neuint.2019.104515</Citation></Reference><Reference><Citation>Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. FEBS Lett. 2000;478(1-2):159-165. https://doi.org/10.1016/S0014-5793(00)01827-5</Citation></Reference><Reference><Citation>Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol. 2010;161(2):241-270. https://doi.org/10.1111/j.1476-5381.2010.00815.x</Citation></Reference><Reference><Citation>Talley EM, Solorzano G, Lei Q, Kim D, Bayliss DA. CNS distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci. 2001;21(19):7491-7505. http://www.ncbi.nlm.nih.gov/pubmed/11567039?dopt=Citation</Citation></Reference><Reference><Citation>Berg AP, Talley EM, Manger JP, Bayliss DA. Motoneurons express heteromeric TWIK-related acid-sensitive K+ (TASK) channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits. J Neurosci. 2004;24(30):6693-6702. https://doi.org/10.1523/JNEUROSCI.1408-04.2004</Citation></Reference><Reference><Citation>Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010;460(2):525-542. https://doi.org/10.1007/s00424-010-0809-1</Citation></Reference><Reference><Citation>Lu YM, Yin HZ, Chiang J, Weiss JH. Ca(2+)-permeable AMPA/kainate and NMDA channels: high rate of Ca2+ influx underlies potent induction of injury. J Neurosci. 1996;16(17):5457-5465.</Citation></Reference><Reference><Citation>Tymianski M, Charlton MP, Carlen PL, Tator CH. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci. 1993;13(5):2085-2104. https://doi.org/10.1523/JNEUROSCI.13-05-02085.1993</Citation></Reference><Reference><Citation>Randall RD, Thayer SA. Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons. J Neurosci. 1992;12(5):1882-1895. https://doi.org/10.1523/JNEUROSCI.12-05-01882.1992</Citation></Reference><Reference><Citation>Simms BA, Zamponi GW. Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron. 2014;82(1):24-45. https://doi.org/10.1016/j.neuron.2014.03.016</Citation></Reference><Reference><Citation>Santos-Nogueira E, Lopez-Serrano C, Hernandez J, et al. Activation of lysophosphatidic acid receptor type 1 contributes to pathophysiology of spinal cord injury. J Neurosci. 2015;35(28):10224-10235. https://doi.org/10.1523/JNEUROSCI.4703-14.2015</Citation></Reference><Reference><Citation>Srikanth M, Chew WS, Hind T, et al. Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice. Eur J Pharmacol. 2018;841:49-56. https://doi.org/10.1016/j.ejphar.2018.10.005</Citation></Reference><Reference><Citation>Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55(7):1192-1214. https://doi.org/10.1194/jlr.R046458</Citation></Reference><Reference><Citation>Fukushima N, Weiner JA, Chun J. Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev Biol. 2000;228(1):6-18. https://doi.org/10.1006/dbio.2000.9930</Citation></Reference><Reference><Citation>Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762(11-12):1068-1082. http://www.ncbi.nlm.nih.gov/pubmed/16806844?dopt=Citation</Citation></Reference><Reference><Citation>Perrakis A, Moolenaar WH. Autotaxin: structure-function and signaling. J Lipid Res. 2014;55(6):1010-1018. https://doi.org/10.1194/jlr.R046391</Citation></Reference><Reference><Citation>Chen X, Talley EM, Patel N, et al. Inhibition of a background potassium channel by Gq protein alpha-subunits. Proc Natl Acad Sci USA. 2006;103(9):3422-3427.Available from http://www.ncbi.nlm.nih.gov/pubmed/16492788?dopt=Citation</Citation></Reference><Reference><Citation>Arakawa Y, Nishijima C, Shimizu N, Urushidani T. Survival-promoting activity of nimodipine and nifedipine in rat motoneurons: implications of an intrinsic calcium toxicity in motoneurons. J Neurochem. 2002;83(1):150-156. https://doi.org/10.1046/j.1471-4159.2002.01126.x</Citation></Reference><Reference><Citation>Kaiser M, Maletzki I, Hulsmann S, et al. Progressive loss of a glial potassium channel (KCNJ10) in the spinal cord of the SOD1 (G93A) transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2006;99(3):900-912. https://doi.org/10.1111/j.1471-4159.2006.04131.x</Citation></Reference><Reference><Citation>Sunico CR, Dom&#xed;nguez G, Garc&#xed;a-Verdugo JM, Osta R, Montero F, Moreno-L&#xf3;pez B. Reduction in the motoneuron inhibitory/excitatory synaptic ratio in an early-symptomatic mouse model of amyotrophic lateral sclerosis. Brain Pathol. 2011;21(1):1-15.</Citation></Reference><Reference><Citation>Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic acid signaling. Biomol Ther. 2015;23(1):1-11. https://doi.org/10.4062/biomolther.2014.109</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>